In the treatment of cancer, the efficacy of antitumor immunity is predominantly associated with the functionality of CD3+ T cells, which initiate the immune response by recognizing tumor-associated antigens, and CD4+ T cells, which primarily function through the paracrine immune response by activating CD8+ T cells and enhancing the antitumor immune response (95). The gene discussed is CD8A; the disease is neoplasm.